Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
NCT00922584
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
65
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
sorafenib (Nexavar)
Sponsor
Chinese Society of Lung Cancer